Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)

This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or seve…

Chronic Graft-versus-host-disease

Estimated

~$10 – $8,750

Incyte CorporationNCT06585774

Phase 2

A Phase 2, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Leas…

Chronic Graft-versus-host-disease

Estimated

~$10 – $8,750

Incyte CorporationNCT07124078

Phase 1

UW23129: A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells …

XerostomiaGraft-versus-host-diseaseSjogren's Disease

Estimated

~$10 – $6,250

University of Wisconsin, MadisonNCT06392711

Phase 2

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractor…

Chronic Graft-versus-host-disease

Estimated

~$10 – $8,750

Syndax PharmaceuticalsNCT04710576

Observational

A Feasibility Study of Using the CiniMacs® Device for Alpha/Best T-Cell Depletion in Stem Cell Transplant Recipients

Patients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD). In certain clinical situation…

Graft Vs Host DiseaseGraft-versus-host-disease

Estimated

~$10 – $7,500

Christopher DvorakNCT04337515

Phase 1

An Open-Label Phase I Study of JAK Inhibitor Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling do…

Graft Vs Host DiseaseGraft-versus-host-diseaseGraft Versus Host Disease

Estimated

~$10 – $6,250

Washington University School of MedicineNCT06008808

Observational

Impact of Exercise on the Complications of Corticosteroids in Patients With Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplantation: the RESTART Trial

This study is about determining if an aerobic and resistance exercise intervention is feasible in patients diagnosed with acute or chronic GVHD (Graft-Versus-H…

Graft Vs Host DiseaseAcute-graft-versus-host DiseaseChronic Graft-versus-host-disease

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT05236062